Last year, Bioventus Inc generated 279.06M USD for its biggest-performing segment, Pain Treatments. The United States made the largest contribution, accounting for 502.10M USD last year. For the latest quarter, Bioventus Inc reported the revenue of 81.75M USD for the period ending 2026-06-27, which came from the top-performing segment, Pain Treatments. United States contributed the highest revenue, at 134.47M USD.

By Business

Revenue

Proportion

Annual

Annual

Quarterly

Pain Treatments

Surgical solutions

Restorative Therapies

Pain Treatments and Joint Preservation

Bone grafts substitutes

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

FY2018

Pain Treatments

279.06M(49.12%)

261.29M(31.31%)

220.80M(30.12%)

--(--)

Surgical solutions

203.65M(35.85%)

189.25M(22.68%)

154.47M(21.07%)

141.16M(27.56%)

--(--)

Restorative Therapies

85.37M(15.03%)

122.74M(14.71%)

137.07M(18.70%)

154.63M(30.20%)

121.57M(28.21%)

88.62M(27.59%)

103.50M(30.43%)

121.03M(37.92%)

Pain Treatments and Joint Preservation

--(--)

261.29M(31.31%)

220.80M(30.12%)

216.32M(42.24%)

221.61M(51.43%)

171.18M(53.30%)

182.08M(53.53%)

155.58M(48.74%)

Bone grafts substitutes

--(--)

87.72M(20.36%)

61.36M(19.11%)

54.55M(16.04%)

42.57M(13.34%)

By Region

Revenue

Proportion

Annual

Annual

Quarterly

United States

International

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

FY2018

United States

502.10M(88.38%)

506.81M(88.41%)

449.86M(87.80%)

455.25M(88.90%)

387.55M(89.94%)

293.70M(91.45%)

305.07M(89.69%)

282.89M(88.63%)

International

65.99M(11.62%)

66.47M(11.59%)

62.48M(12.20%)

56.87M(11.10%)

43.34M(10.06%)

27.46M(8.55%)

35.07M(10.31%)

36.28M(11.37%)